- Oroxin B
-
- $75.00
-
2026-07-27
- CAS:114482-86-9
- Purity: 99.87%
- Supply Ability: 10g
- Oroxin B
-
-
2023-02-24
- CAS:114482-86-9
- Min. Order: 5mg
- Purity: ≥98%(HPLC)
- Supply Ability: 10 g
|
| | Baicalin-7-diglucoside Basic information |
| | Baicalin-7-diglucoside Chemical Properties |
| Boiling point | 957.5±65.0 °C(Predicted) | | density | 1.76 | | storage temp. | 4°C, protect from light | | solubility | Soluble in methanol and water | | form | powder | | pka | 5.91±0.40(Predicted) | | color | Yellowish | | InChIKey | HAYLVXFWJCKKDW-WEYZNFCFNA-N |
| Safety Statements | 24/25 | | HS Code | 29389090 |
| | Baicalin-7-diglucoside Usage And Synthesis |
| Chemical Properties | Soluble in methanol, ethanol, water, etc., insoluble in petroleum ether and chloroform. Derived from Oroxylum indicum, Bignoniaceae | | Uses | Oroxin B is a component of the seed of O. (oroxylum) indicum and is used in traditional Chinese medicine for antiinflammatory, analgesic and other functions. It also has been observed to selectively induce tumor-suppressive ER stress and inhibits tumor-adaptive ER stress in B-lymphoma cells attenuating tumor growth. | | in vivo | Oroxin B (30 mg/kg, i.p., 28 days) induces malignant lymphoma cell ER stress, and inhibits tumor growth in human lymphoma cell (Raji cell) xenograft model[2].
Oroxin B (160 μM of 10 μL, injected into the knee joints of mice) protects articular cartilage in destabilized medial meniscus (DMM) induced mice OA[3].
Oroxin B (200 mg/kg/day, oral gavage) relieves hepatic inflammation and inhibits MAFLD progression in HFD-fed rats[4].
| Animal Model: | Human lymphoma cell (Raji cell) xenograft model[2] | | Dosage: | 30 mg/kg | | Administration: | i.p., 28 days | | Result: | Induced malignant lymphoma cell ER stress.
Inhibited tumor growth.
Prolonged overall survival of tumor-bearing mice. |
| Animal Model: | HFD-fed rats[4] | | Dosage: | 200 mg/kg/day | | Administration: | oral gavage | | Result: | Reduced the levels of plasma lipids, LPS, IL-6, and TNF-α.
Inhibited liver fibrosis by reducing collagen deposition.
|
|
| | Baicalin-7-diglucoside Preparation Products And Raw materials |
|